During MeTHOS study will be collected Real World Data the clinical practice regarding Thromboprophylaxis in high thrombotic risk solid tumors patients undergoing surgical and /or chemotherapeutical treatment, for one year following the protocol initiation date. Specifically focus will be on the following: * Number of thrombotic events * Anti-thrombotic management dosage \& duration * Any bleedings related to anticoagulation * Patients' adherence and compliance
Study Type
OBSERVATIONAL
Enrollment
600
Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
Metaxa Hopital
Piraeus, Attica, Greece
RECRUITINGNumber of thrombotic events
Measure the number of thrombotic events in the population
Time frame: Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
Number of bleedings related to anticoagulation
Measure the number of observed bleeding events caused by the anticoagulation treatment
Time frame: Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
Anticoagulation drug dosage
Record the antithrombotic drug dosage (IU/day), aiming to investigate the role of dosage for thrombotic events and bleedings (primary outcomes)
Time frame: Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
Anticoagulation drug duration
Record the antithrombotic drug duration (in days). The aim is to investigate the role of antithrombotic duration for thrombotic events and bleedings (primary outcomes)
Time frame: Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
Patients' compliance to anticoagulation treatment
Record the compliance of patients' in antithrombotic treatment. A patient is considered to be compliant if the anticoagulation treatment was administered as prescribed (usually every day), otherwise it is non-compliant. The aim is to investigate the role of patient compliance for thrombotic events and bleedings (primary outcomes).
Time frame: Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Anticoagulation drug agent
Record the anticoagulation drug agent. The aim is to investigate the role of different agents for thrombotic events and bleedings (primary outcomes)
Time frame: Each subject's participation will last from inclusion (enrolment visit) to follow up visit (if applicable; four weeks post hospital discharge)